Can abatacept induce immunological remission under tight control in rheumatoid arthritis patient?

Can abatacept induce immunological remission under tight control in rheumatoid arthritis patient? - Airtight study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005570

Enrollment

Registered

2011-06-01

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who had a diagnosis by 2010 ACR/EULAR rheumatoid arthritis classification criteria and then will receive one of biological agents Including patients with switching of biologic agents

Exclusion criteria

Exclusion criteria: Patients with leukocyte less than 4000/mm3, lymphocytes 1000/mm3, ADL activity in class IV, interstitial pneumonia, active hepatitis B, active tuberculosis, compromised condition, malignant tumor

Design outcomes

Primary

Measure	Time frame
Changes in values of anti-cyclic citrullinated peptide antibody, rheumatoid factor, IgG that lack galactose, and type IgG rheumatoid factor	—

Secondary

Measure	Time frame
Scores in joint echo for hand and wrist	—

Countries

Japan

Contacts

Public ContactTatsuya Koike

Osaka City University Medical School Dept. of orthopaedic surgery

tatsuya@med.osaka-cu.ac.jp

Outcome results